Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALLEX 4 long-term extension in type 2 diabetes
2004-005243-97Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tesaglitazar, glibenclamide in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Sep 2005; status: completed.
02
Drugs
tesaglitazarglibenclamide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2004-005243-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005243-97.